Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
33%
Ph phase_4
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Active, not recruiting1
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

active_not_recruiting133%
completed133%
withdrawn133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_4

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)

NCT07547878
withdrawnphase_1

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

NCT04878315
completedphase_3

Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia

NCT03389724

Clinical Trials (3)

Showing 3 of 3 trials
NCT07547878Phase 4

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)

Active Not Recruiting
NCT04878315Phase 1

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Withdrawn
NCT03389724Phase 3

Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3